http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009016358-A3

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd84c2ae7488330bd411f72164047512
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8d57626064ed8a104abce020b25cd4b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5053f82a7cd17c60822674b657cfb89e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bd01fb06d2225aa768bff36a8c38fa68
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-209
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-216
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-40
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-192
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
filingDate 2008-07-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c3959e884e76459e81d5963292431b92
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6535db2a2433db80621a032b099840ec
publicationDate 2009-07-23-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-2009016358-A3
titleOfInvention Pharmaceutical compositions and process for making them
abstract Amorphous HMG CoA reductase inhibitors, especially amorphous atorvastatin, are described. Also described are pharmaceutical combinations comprising amorphous HMG CoA reductase inhibitors in combination with cholesterol absorption inhibitors or fibrates. A method of manufacturing the compositions using a hot melt extrusion process are also described.
priorityDate 2007-07-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008063766-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2006269608-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007014846-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006059224-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006134604-A1
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395935
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60823
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60822
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395936

Total number of triples: 40.